Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830830 · ClinicalTrials.gov registry record · Phase 4
TREAD-20 Extension - Treatment of Knee Pain Due to Osteoarthritis
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00830830 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 40 participants.
The verdict
NCT00830830, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This extended study will evaluate the efficacy and safety of intra-articular injections of 20mg/2ml dose HYALGAN in patients with pain due to osteoarthritis (OA) of the knee.
Interventions
- DRUG Hyalgan (sodium hyaluronate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00830830
The ClinicalTrials.gov registry entry for NCT00830830 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyalgan (sodium hyaluronate) is the first listed.
NCT00830830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00830830 about?
NCT00830830 is a clinical study titled "TREAD-20 Extension - Treatment of Knee Pain Due to Osteoarthritis". This extended study will evaluate the efficacy and safety of intra-articular injections of 20mg/2ml dose HYALGAN in patients with pain due to osteoarthritis (OA) of the knee.
What is the current status of trial NCT00830830?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2005-12. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00830830?
The interventions under investigation include: Hyalgan (sodium hyaluronate) (DRUG).
Who is sponsoring clinical trial NCT00830830?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.